Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US6635646B1 · kind B1 · utility
14Cited by
1References
30Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 1, 2000 |
| Grant date | Oct 21, 2003 |
| Priority date | — |
| Expiry date | May 1, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.